Carcinotech and CELLINK plan to revolutionize the drug discovery market by leveraging CELLINK’s bioprinting solutions and Carcinotech’s expertise in producing 3D bioprinted living tumors to provide protocols for users to develop cutting-edge cancer models.

Newly-launched module set to accelerate drug discovery in therapeutic areas such as neuropsychiatry, epilepsy and neurodegeneration.

External placement marks a key milestone in the development of Evonetix’s benchtop DNA synthesis technology, in preparation for customer use and commercialization.

Haier Biomedical is pleased to announce the launch of its new line of energy efficient TwinCool Frequency Conversion ULT Freezers for pharmaceutical, clinical research and public health laboratories.

The FlowLab Column™ from Uniqsis is an affordable flow chemistry system designed specifically for high temperature and pressure catalysis applications.

Investment to expand cell line development capabilities and accelerate customer workflows, as part of its diverse and tailored antibody solutions.

SPARTA technology to accelerate the development, manufacture and quality control of nanoparticles used for gene therapies, vaccines, and cancer drugs.

AMSBIO, in collaboration with the University of Strathclyde (UK), announce the release of a poster that describes a comprehensive assessment of the effects of three different cryopreservation reagents.

Corgenix, a Sebia Group company, CAP/CLIA clinical laboratory, positions Sebia to globally commercialize M-inSight®, a novel non-invasive liquid biopsy assay for Minimal Residual Disease (MRD) monitoring in multiple myeloma.

Superior thermal performance and enhanced usability for PCR applications, such as sequencing, cloning, and genotyping.